Clavis Pharma Licenses Rights to hENT1 antibody to Ventana Medical Systems, Inc.
The agreement reinforces the collaboration agreement announced on April 22, 2010 between Ventana and Clovis Oncology, Clavis Pharma’s partner for CP-4126, for the development of a companion diagnostic to CP-4126 (also known as CO-101) for clinical and commercial use.
Under the terms of the agreement, Ventana gains exclusive access from Clavis Pharma to the hENT1 antibody and hybridoma line around which Ventana will seek to develop an immuno-histochemistry (IHC) assay for use in Clovis Oncology’s clinical trials to identify patients with low level of hENT1 expression in the tumor. All costs under this agreement will be borne by Clovis Oncology.
Clavis Pharma also retains the rights to use the hENT1 antibody to develop companion diagnostics on other assay platforms for the evaluation of hENT1 status in regard to clinical and commercial use with its other product candidates, such as elacytarabine and CP-4200.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.